MDD in 2018
Major Depressive Disorder in 2018: Challenges, Considerations, and the Role of an FDA-Approved Treatment Option
Speakers: Adam Ashton, MDPrakash Masand, MD
Duration: 30 minutes
Presented on: August 24, 2018
*This session is not eligible for AMA PRA Category 1 CreditsTM
Adam Ashton, MD
Adam Ashton, MDAdam Ashton, MD, is a Clinical Professor of Psychiatry with the Jacobs School of Medicine and Biomedical Sciences in Buffalo, New York, and a distinguished fellow of the American Psychiatric Association, along with working in full-time private practice with Suburban Psychiatric Associates. He has over 100 published book chapters, abstracts, posters, and articles and has written extensively for psychiatric journals on treatment-induced sexual dysfunction. He has lectured widely, having given over 2000 presentations and has been an invited guest lecturer at numerous national symposia. He also was awarded the 2007 State University of New York at Buffalo Department of Psychiatry teaching award for outstanding contributions to medical student education.
Prakash Masand, MD
Prakash Masand, MDPrakash Masand, MD, serves as Adjunct Professor at the Academic Medicine Education Institute, Duke-National University of Singapore Medical School (Duke-NUS) and is Founder, Chairman, and CEO of Centers of Psychiatric Excellence (COPE). Dr. Masand’s clinical research interests include psychopharmacology, novel antipsychotics, psychiatric disorders in the medically ill, treatment-resistant depression, irritable bowel syndrome and its relationship to psychiatric illness, and the use of psychostimulants in the medically ill.